Q1 2025 Biogen Inc Earnings Call Transcript
Key Points
- Biogen Inc (BIIB) reported a strong start to the year with a significant increase in revenue from new product launches, contributing to 45% of product revenue.
- The company received FDA Fast Track designation for its ASO targeting BIIB080, indicating confidence in its potential for Alzheimer's treatment.
- LEQEMBI received marketing authorization in the EU, marking a significant regulatory endorsement for its efficacy and safety profile.
- Biogen Inc (BIIB) has a robust pipeline with five Phase III studies initiating this year, indicating a maturation of its pipeline.
- The company maintains a strong balance sheet, allowing for continued investment in internal and external growth opportunities.
- Biogen Inc (BIIB) faces declining revenue in its MS franchise due to competition from biosimilars and generics.
- The launch of LEQEMBI has been challenging due to the workload it imposes on treating physicians.
- The company anticipates a mid-single-digit percentage decline in total revenue for 2025, primarily driven by a decline in the MS business.
- Biogen Inc (BIIB) is experiencing impacts from the Medicare tax, affecting net sales growth.
- The tariff landscape remains uncertain, posing potential risks to the company's financial outlook.
Good morning. My name is Melinda, and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Biogen first quarter 2025 earnings call and business update. (Operator Instructions). Today's conference is being recorded. Thank you.
I would now like to turn the conference over to Mr. Tim Power, Head of Investor Relations. Mr. Power, you may begin your conference.
Thanks, Melinda. Good morning, and welcome to Biogen's first quarter 2025 earnings call. During this call, we'll make forward-looking statements, which involve risks and uncertainties that may cause actual results to differ materially from our forward-looking statements. We provide a comprehensive list of risk factors in our SEC filings, which I encourage you to review.
Our earnings release and other documents related to our results as well as reconciliations between GAAP and non-GAAP results discussed on this call can be found in the Investors section of biogen.com. We've also posted the slides to our
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |


